Has Aparna Kalyan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $156,283 in general payments to Aparna Kalyan, MD across 114 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Aparna Kalyan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Aparna Kalyan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Aparna Kalyan, MD

Hematology & Oncology · Chicago, ILNPI 1447482443

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $98,877 of the $156,283 with a category attached, or 63.3%. 14 manufacturers reported payments, led by AstraZeneca at 39.0% of the total. Among hematology & oncology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$156,283in general payments, 2019–2025

Across 114 payments — averaging $1370.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$61K
E.r. Squibb & Sons, L.L.C.$17K
Genentech USA, Inc.$16K
Exelixis Inc.$14K
Astrazeneca UK Limited$13K
Boston Scientific$9K
plus $26K from 8 others

$3,035,797in research payments, 2019–2025

Across 114 payments — averaging $26,630 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Deciphera Pharmaceuticals Inc.$1.3M
AstraZeneca$804K
Seagen Inc.$374K
Astrazeneca UK Limited$242K
Clovis Oncology, Inc.$116K
QED Therapeutics, Inc.$56K
plus $187K from 6 others

What the payments were for

Consulting fees$98,87763%
Speaking & faculty fees$50,20032%
Travel & lodging$4,0883%
Food & beverage$3,1182%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	34	$61,000
E.r. Squibb & Sons, L.L.C.	18	$17,209
Genentech USA, Inc.	7	$16,496
Exelixis Inc.	8	$13,928
Astrazeneca UK Limited	4	$12,803
Boston Scientific	16	$8,842
Deciphera Pharmaceuticals Inc.	4	$7,005
Agios Pharmaceuticals, Inc.	5	$3,803
Corcept Therapeutics	7	$3,661
Eisai Inc.	3	$3,012
Servier Pharmaceuticals LLC	2	$2,940
Siemens Medical Solutions USA, Inc.	1	$2,700
Ipsen Biopharmaceuticals, Inc	3	$1,655
Incyte Corporation	2	$1,230

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

IMFINZI$46,538
Cabometyx$13,928
TECENTRIQ$8,260
QINLOCK$6,917
TIBSOVO$6,662
GENERAL PAIN MANAGEMENT$5,375
LENVIMA$2,947
TheraSphere Y90 Glass Microspheres 10 GBq$2,220
SOMATULINE DEPOT$1,634
PEMAZYRE$1,230
THERASPHERE$750
SPYGLASS$155
ONIVYDE$134

How this compares

$156,283 in reported general payments places this provider in the 95th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois →

Medicare billing

Part B allowed, 2024

$2,945,552

Medicare patients

419

Services billed

100,553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
CreonLipase/Protease/Amylase	16	$49,918
EliquisApixaban	13	$11,447
XareltoRivaroxaban	11	$7,347
Prochlorperazine Maleate	23	$174
Ondansetron Hcl	18	$93

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Chicago

Michael BishopChicago$974K
Jamile ShammoChicago$910K
Young Kwang ChaeChicago$563K
Irfan MirzaChicago$544K
Marina GarassinoChicago$397K
Chih-Yi LiaoChicago$317K
Rita NandaChicago$286K
Shuo MaChicago$280K
Santosh SarafChicago$275K
Peter RiedellChicago$273K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →